熱門資訊> 正文
Dermata Therapeutics定价350万美元股权发行
2024-09-17 12:54
- Late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases - Dermata Therapeutics (NASDAQ:DRMA) announced the sale of 1.91M shares and warrants to purchase shares at $1.83 per share.
- Gross proceeds from the offering are expected to be approximately $3.5M.
- The closing of the offering is expected to occur on or about September 17, 2024.
- The company expects to use net proceeds for general corporate purposes.
- The stock price dipped 3% on Monday during after hours of trade.
More on Dermata Therapeutics
- Seeking Alpha’s Quant Rating on Dermata Therapeutics
- Historical earnings data for Dermata Therapeutics
- Financial information for Dermata Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
